Akari Therapeutics (STU:CLA1) E10: €0.00 (As of Mar. 2026)


STU:CLA1 Akari Therapeutics PLC STU:CLA1
32 GF Score
Price €134.40
View Full Analysis

What is Akari Therapeutics E10?

Akari Therapeutics STU:CLA1 32 E10 is €0.00 as of Mar. 2026. GuruFocus rates STU:CLA1 with a GF Score™ of 32/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Akari Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-10), Akari Therapeutics's current stock price is €134.40. Akari Therapeutics's E10 for the quarter that ended in Mar. 2026 was €0.00. Akari Therapeutics's Shiller PE Ratio of today is .


Akari Therapeutics  (STU:CLA1) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Akari Therapeutics E10 Related Terms


Akari Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Akari Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akari Therapeutics E10 Chart

Akari Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -2,786.89 -5,007.25 0.00

Akari Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:CLA1 vs MBRX, JAGX, ANEB: E10 Comparison

For the Biotechnology subindustry, Akari Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Shiller PE Ratio falls into.


STU:CLA1
32GF Score
Akari Therapeutics PLC STU:CLA1
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akari Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akari Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Akari Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201603 -182.110 238.132 -252.528
201606 -712.000 241.018 -975.494
201609 -25.307 241.428 -34.614
201612 -758.400 241.432 -1,037.284
201703 -748.000 243.801 -1,013.119
201706 -19.347 244.955 -26.081
201709 -671.200 246.819 -897.982
201712 -676.000 246.524 -905.486
201803 -56.923 249.554 -75.321
201806 -684.800 251.989 -897.380
201809 -161.154 252.439 -210.804
201812 -156.271 251.233 -205.398
201903 -113.992 254.202 -148.078
201906 -181.374 256.143 -233.823
201909 -94.543 256.759 -121.590
201912 -262.953 256.974 -337.896
202003 -107.765 258.115 -137.866
202006 -176.029 257.797 -225.476
202009 18.320 260.280 23.242
202012 -455.121 260.474 -576.975
202103 -101.979 264.877 -127.134
202106 -75.012 271.696 -91.168
202109 -21.243 274.310 -25.572
202112 -88.160 278.802 -104.417
202203 -70.173 287.504 -80.597
202206 -72.429 296.311 -80.716
202212 0.000 296.797 0.000
202303 9.876 301.836 10.804
202306 -29.200 305.109 -31.603
202309 -21.272 307.789 -22.822
202312 42.554 306.746 45.810
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 -5.418 315.605 -5.669
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.00 mean?
Akari Therapeutics (STU:CLA1) has a E10 of €0.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Akari Therapeutics and its competitors.
Is Akari Therapeutics' E10 too high?
Akari Therapeutics' current E10 is €0.00. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' E10 compare to MBRX and JAGX?
Akari Therapeutics' E10 of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Akari Therapeutics and its competitors. Akari Therapeutics's current E10 is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (STU:CLA1) has a current E10 of €0.00. The current E10 is €0.00. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Akari Therapeutics (STU:CLA1), the current E10 is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Other Exchanges AKTX:USA
Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score

Get the complete analysis for STU:CLA1

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.40
Price